0001562180-24-000784.txt : 20240129
0001562180-24-000784.hdr.sgml : 20240129
20240129175157
ACCESSION NUMBER: 0001562180-24-000784
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240125
FILED AS OF DATE: 20240129
DATE AS OF CHANGE: 20240129
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Paggiarino Dario A.
CENTRAL INDEX KEY: 0001574261
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51122
FILM NUMBER: 24575176
MAIL ADDRESS:
STREET 1: 4025 SORRENTO VALLEY BLVD.
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001314102
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 262774444
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-926-5000
MAIL ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida Corp.
DATE OF NAME CHANGE: 20080619
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida LTD
DATE OF NAME CHANGE: 20050111
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-01-25
false
0001314102
EyePoint Pharmaceuticals, Inc.
EYPT
0001574261
Paggiarino Dario A.
C/O EYEPOINT PHARMACEUTICALS, INC.
480 PLEASANT STREET
WATERTOWN
MA
02472
false
true
false
false
Chief Medical Officer
true
Common Stock
2024-01-25
4
M
false
300.00
13.13
A
36805.00
D
Common Stock
2024-01-25
4
M
false
300.00
12.90
A
37105.00
D
Common Stock
2024-01-25
4
S
false
300.00
25.00
D
36805.00
D
Common Stock
2024-01-25
4
S
false
300.00
25.00
D
36505.00
D
Stock Option (Right to Buy)
13.13
2024-01-25
4
M
false
300.00
0.00
D
2031-02-09
Common Stock
300.00
51304.00
D
Stock Option (Right to Buy)
12.90
2024-01-25
4
M
false
300.00
0.00
D
2030-02-28
Common Stock
300.00
16635.00
D
The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.
The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020
/s/ Ron Honig, Attorney-in-Fact
2024-01-29